{"skill":{"slug":"alexion-pharma","displayName":"Alexion Pharma","summary":"开发全球首款补体C5抑制孤儿药Soliris，专注补体介导罕见病治疗，2021年被阿斯利康以390亿美元收购。","tags":{"latest":"1.0.0"},"stats":{"comments":0,"downloads":98,"installsAllTime":0,"installsCurrent":0,"stars":0,"versions":1},"createdAt":1778245483588,"updatedAt":1778492880688},"latestVersion":{"version":"1.0.0","createdAt":1778245483588,"changelog":"- 初始发布，详细介绍Alexion Pharmaceuticals的历史发展、核心产品Soliris与Ultomiris、商业模式和被阿斯利康收购历程。\n- 提供罕见病药物市场和补体系统靶向疗法的分析信息。\n- 总结关键销售数据、并购金额及罕见病药物行业护城河。\n- 列出Soliris高定价及其对罕见病治疗行业的影响和讨论。","license":"MIT-0"},"metadata":null,"owner":{"handle":"hanxueyuan","userId":"s17eht14r6y7ztwaw37n96ka7583eghn","displayName":"hanxueyuan","image":"https://avatars.githubusercontent.com/u/16717383?v=4"},"moderation":null}